CTLA4 and cervical carcinoma: Recently approved a block of cervical cancer cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) of a variety of therapeutic antibodies, and other immune targeted clinical checkpoint blocker [22], but questions remain about the blocker’s treatment effect and patient prognosis.